Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
对于既往接受过至少两线治疗后复发或难治性大B细胞淋巴瘤的老年患者和/或ECOG评分较差的患者，axicabtagene ciloleucel与化疗免疫疗法相比的疗效
期刊:American Journal of Hematology
影响因子:9.9
doi:10.1002/ajh.27283
Lunning, Matthew A; Wang, Hai-Lin; Hu, Zhen-Huan; Locke, Frederick L; Siddiqi, Tanya; Jacobson, Caron A; Ahmed, Sairah; Miklos, David B; Lin, Yi; Hill, Brian T; Ghobadi, Armin; Neelapu, Sattva S; Westin, Jason; Dieyi, Chrisopher; Field, Polly; Miao, Harry; Shahani, Shilpa A; Patel, Anik; Spooner, Clare; Fu, Christine; Muramoto, David; Xu, Hairong; Pasquini, Marcelo C
